

Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market 2023 by Company, Regions, Type and Application, Forecast to 2029

<https://marketpublishers.com/r/G7E34A622529EN.html>

Date: January 2023

Pages: 86

Price: US\$ 3,480.00 (Single User License)

ID: G7E34A622529EN

Abstracts

The human immunodeficiency virus (HIV) is a lentivirus (a subgroup of retrovirus) that causes HIV infection and over time acquired immunodeficiency syndrome (AIDS). AIDS is a condition in humans in which progressive failure of the immune system allows life-threatening opportunistic infections and cancers to thrive.

According to our (Global Info Research) latest study, the global Human Immunodeficiency Virus (HIV)-1 Therapeutics market size was valued at USD 12220 million in 2022 and is forecast to a readjusted size of USD 12890 million by 2029 with a CAGR of 0.8% during review period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.

The key factors responsible for driving the market growth include the increasing incidence of HIV infections especially amongst the youth due to unprotected sexual practices, exposure to needles or syringes contaminated with infected body fluids or tissues, lack of awareness regarding transmission risk factors, etc.

This report is a detailed and comprehensive analysis for global Human Immunodeficiency Virus (HIV)-1 Therapeutics market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided.

Key Features:

Global Human Immunodeficiency Virus (HIV)-1 Therapeutics market size and forecasts, in consumption value (\$ Million), 2018-2029

Global Human Immunodeficiency Virus (HIV)-1 Therapeutics market size and forecasts by region and country, in consumption value (\$ Million), 2018-2029

Global Human Immunodeficiency Virus (HIV)-1 Therapeutics market size and forecasts, by Type and by Application, in consumption value (\$ Million), 2018-2029

Global Human Immunodeficiency Virus (HIV)-1 Therapeutics market shares of main players, in revenue (\$ Million), 2018-2023

The Primary Objectives in This Report Are:

To determine the size of the total market opportunity of global and key countries

To assess the growth potential for Human Immunodeficiency Virus (HIV)-1 Therapeutics

To forecast future growth in each product and end-use market

To assess competitive factors affecting the marketplace

This report profiles key players in the global Human Immunodeficiency Virus (HIV)-1 Therapeutics market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include AbbVie, Inc.(U.S.), Merck & Co., Inc. (U.S.), Bristol-Myers Squibb Company (U.S.), Boehringer Ingelheim GmbH (Germany) and Genentech, Inc. (U.S.) and etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.

Market segmentation

Human Immunodeficiency Virus (HIV)-1 Therapeutics market is split by Type and by Application. For the period 2018-2029, the growth among segments provide accurate calculations and forecasts for consumption value by Type and by Application. This

analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type

Nucleoside-Analog Reverse Transcriptase Inhibitors (NRTIs)

Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)

Entry and Fusion Inhibitors

Protease Inhibitors (PIs)

Integrase Inhibitors

Coreceptor Antagonists

Market segment by Application

Hospitals

Clinics

Labs

Market segment by players, this report covers

AbbVie, Inc.(U.S.)

Merck & Co., Inc. (U.S.)

Bristol-Myers Squibb Company (U.S.)

Boehringer Ingelheim GmbH (Germany)

Genentech, Inc. (U.S.)

Cipla, Inc. (India)

Market segment by regions, regional analysis covers

North America (United States, Canada, and Mexico)

Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)

Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)

South America (Brazil, Argentina and Rest of South America)

Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)

The content of the study subjects, includes a total of 13 chapters:

Chapter 1, to describe Human Immunodeficiency Virus (HIV)-1 Therapeutics product scope, market overview, market estimation caveats and base year.

Chapter 2, to profile the top players of Human Immunodeficiency Virus (HIV)-1 Therapeutics, with revenue, gross margin and global market share of Human Immunodeficiency Virus (HIV)-1 Therapeutics from 2018 to 2023.

Chapter 3, the Human Immunodeficiency Virus (HIV)-1 Therapeutics competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.

Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2018 to 2029.

Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2018 to 2023. and Human Immunodeficiency Virus (HIV)-1 Therapeutics market forecast, by regions, type and application, with consumption value, from 2024 to 2029.

Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War

Chapter 12, the key raw materials and key suppliers, and industry chain of Human Immunodeficiency Virus (HIV)-1 Therapeutics.

Chapter 13, to describe Human Immunodeficiency Virus (HIV)-1 Therapeutics research findings and conclusion.

Contents

1 MARKET OVERVIEW

- 1.1 Product Overview and Scope of Human Immunodeficiency Virus (HIV)-1 Therapeutics
- 1.2 Market Estimation Caveats and Base Year
- 1.3 Classification of Human Immunodeficiency Virus (HIV)-1 Therapeutics by Type
 - 1.3.1 Overview: Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Type: 2018 Versus 2022 Versus 2029
 - 1.3.2 Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Value Market Share by Type in 2022
 - 1.3.3 Nucleoside-Analog Reverse Transcriptase Inhibitors (NRTIs)
 - 1.3.4 Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
 - 1.3.5 Entry and Fusion Inhibitors
 - 1.3.6 Protease Inhibitors (PIs)
 - 1.3.7 Integrase Inhibitors
 - 1.3.8 Coreceptor Antagonists
- 1.4 Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market by Application
 - 1.4.1 Overview: Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Application: 2018 Versus 2022 Versus 2029
 - 1.4.2 Hospitals
 - 1.4.3 Clinics
 - 1.4.4 Labs
- 1.5 Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size & Forecast
- 1.6 Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size and Forecast by Region
 - 1.6.1 Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Region: 2018 VS 2022 VS 2029
 - 1.6.2 Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Region, (2018-2029)
 - 1.6.3 North America Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size and Prospect (2018-2029)
 - 1.6.4 Europe Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size and Prospect (2018-2029)
 - 1.6.5 Asia-Pacific Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size and Prospect (2018-2029)
 - 1.6.6 South America Human Immunodeficiency Virus (HIV)-1 Therapeutics Market

Size and Prospect (2018-2029)

1.6.7 Middle East and Africa Human Immunodeficiency Virus (HIV)-1 Therapeutics
Market Size and Prospect (2018-2029)

2 COMPANY PROFILES

2.1 AbbVie, Inc.(U.S.)

2.1.1 AbbVie, Inc.(U.S.) Details

2.1.2 AbbVie, Inc.(U.S.) Major Business

2.1.3 AbbVie, Inc.(U.S.) Human Immunodeficiency Virus (HIV)-1 Therapeutics Product and Solutions

2.1.4 AbbVie, Inc.(U.S.) Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue, Gross Margin and Market Share (2018-2023)

2.1.5 AbbVie, Inc.(U.S.) Recent Developments and Future Plans

2.2 Merck & Co., Inc. (U.S.)

2.2.1 Merck & Co., Inc. (U.S.) Details

2.2.2 Merck & Co., Inc. (U.S.) Major Business

2.2.3 Merck & Co., Inc. (U.S.) Human Immunodeficiency Virus (HIV)-1 Therapeutics Product and Solutions

2.2.4 Merck & Co., Inc. (U.S.) Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue, Gross Margin and Market Share (2018-2023)

2.2.5 Merck & Co., Inc. (U.S.) Recent Developments and Future Plans

2.3 Bristol-Myers Squibb Company (U.S.)

2.3.1 Bristol-Myers Squibb Company (U.S.) Details

2.3.2 Bristol-Myers Squibb Company (U.S.) Major Business

2.3.3 Bristol-Myers Squibb Company (U.S.) Human Immunodeficiency Virus (HIV)-1 Therapeutics Product and Solutions

2.3.4 Bristol-Myers Squibb Company (U.S.) Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue, Gross Margin and Market Share (2018-2023)

2.3.5 Bristol-Myers Squibb Company (U.S.) Recent Developments and Future Plans

2.4 Boehringer Ingelheim GmbH (Germany)

2.4.1 Boehringer Ingelheim GmbH (Germany) Details

2.4.2 Boehringer Ingelheim GmbH (Germany) Major Business

2.4.3 Boehringer Ingelheim GmbH (Germany) Human Immunodeficiency Virus (HIV)-1 Therapeutics Product and Solutions

2.4.4 Boehringer Ingelheim GmbH (Germany) Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue, Gross Margin and Market Share (2018-2023)

2.4.5 Boehringer Ingelheim GmbH (Germany) Recent Developments and Future Plans

2.5 Genentech, Inc. (U.S.)

- 2.5.1 Genentech, Inc. (U.S.) Details
- 2.5.2 Genentech, Inc. (U.S.) Major Business
- 2.5.3 Genentech, Inc. (U.S.) Human Immunodeficiency Virus (HIV)-1 Therapeutics Product and Solutions
- 2.5.4 Genentech, Inc. (U.S.) Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
- 2.5.5 Genentech, Inc. (U.S.) Recent Developments and Future Plans
- 2.6 Cipla, Inc. (India)
 - 2.6.1 Cipla, Inc. (India) Details
 - 2.6.2 Cipla, Inc. (India) Major Business
 - 2.6.3 Cipla, Inc. (India) Human Immunodeficiency Virus (HIV)-1 Therapeutics Product and Solutions
 - 2.6.4 Cipla, Inc. (India) Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
 - 2.6.5 Cipla, Inc. (India) Recent Developments and Future Plans

3 MARKET COMPETITION, BY PLAYERS

- 3.1 Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue and Share by Players (2018-2023)
- 3.2 Market Share Analysis (2022)
 - 3.2.1 Market Share of Human Immunodeficiency Virus (HIV)-1 Therapeutics by Company Revenue
 - 3.2.2 Top 3 Human Immunodeficiency Virus (HIV)-1 Therapeutics Players Market Share in 2022
 - 3.2.3 Top 6 Human Immunodeficiency Virus (HIV)-1 Therapeutics Players Market Share in 2022
- 3.3 Human Immunodeficiency Virus (HIV)-1 Therapeutics Market: Overall Company Footprint Analysis
 - 3.3.1 Human Immunodeficiency Virus (HIV)-1 Therapeutics Market: Region Footprint
 - 3.3.2 Human Immunodeficiency Virus (HIV)-1 Therapeutics Market: Company Product Type Footprint
 - 3.3.3 Human Immunodeficiency Virus (HIV)-1 Therapeutics Market: Company Product Application Footprint
- 3.4 New Market Entrants and Barriers to Market Entry
- 3.5 Mergers, Acquisition, Agreements, and Collaborations

4 MARKET SIZE SEGMENT BY TYPE

4.1 Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Value and Market Share by Type (2018-2023)

4.2 Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Forecast by Type (2024-2029)

5 MARKET SIZE SEGMENT BY APPLICATION

5.1 Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Value Market Share by Application (2018-2023)

5.2 Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Forecast by Application (2024-2029)

6 NORTH AMERICA

6.1 North America Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Value by Type (2018-2029)

6.2 North America Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Value by Application (2018-2029)

6.3 North America Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Country

6.3.1 North America Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Value by Country (2018-2029)

6.3.2 United States Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size and Forecast (2018-2029)

6.3.3 Canada Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size and Forecast (2018-2029)

6.3.4 Mexico Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size and Forecast (2018-2029)

7 EUROPE

7.1 Europe Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Value by Type (2018-2029)

7.2 Europe Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Value by Application (2018-2029)

7.3 Europe Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Country

7.3.1 Europe Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Value by Country (2018-2029)

7.3.2 Germany Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size and Forecast (2018-2029)

7.3.3 France Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size and Forecast (2018-2029)

7.3.4 United Kingdom Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size and Forecast (2018-2029)

7.3.5 Russia Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size and Forecast (2018-2029)

7.3.6 Italy Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size and Forecast (2018-2029)

8 ASIA-PACIFIC

8.1 Asia-Pacific Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Value by Type (2018-2029)

8.2 Asia-Pacific Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Value by Application (2018-2029)

8.3 Asia-Pacific Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Region

8.3.1 Asia-Pacific Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Value by Region (2018-2029)

8.3.2 China Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size and Forecast (2018-2029)

8.3.3 Japan Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size and Forecast (2018-2029)

8.3.4 South Korea Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size and Forecast (2018-2029)

8.3.5 India Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size and Forecast (2018-2029)

8.3.6 Southeast Asia Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size and Forecast (2018-2029)

8.3.7 Australia Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size and Forecast (2018-2029)

9 SOUTH AMERICA

9.1 South America Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Value by Type (2018-2029)

9.2 South America Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption

Value by Application (2018-2029)

9.3 South America Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Country

9.3.1 South America Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Value by Country (2018-2029)

9.3.2 Brazil Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size and Forecast (2018-2029)

9.3.3 Argentina Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size and Forecast (2018-2029)

10 MIDDLE EAST & AFRICA

10.1 Middle East & Africa Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Value by Type (2018-2029)

10.2 Middle East & Africa Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Value by Application (2018-2029)

10.3 Middle East & Africa Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Country

10.3.1 Middle East & Africa Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Value by Country (2018-2029)

10.3.2 Turkey Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size and Forecast (2018-2029)

10.3.3 Saudi Arabia Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size and Forecast (2018-2029)

10.3.4 UAE Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size and Forecast (2018-2029)

11 MARKET DYNAMICS

11.1 Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Drivers

11.2 Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Restraints

11.3 Human Immunodeficiency Virus (HIV)-1 Therapeutics Trends Analysis

11.4 Porters Five Forces Analysis

11.4.1 Threat of New Entrants

11.4.2 Bargaining Power of Suppliers

11.4.3 Bargaining Power of Buyers

11.4.4 Threat of Substitutes

11.4.5 Competitive Rivalry

11.5 Influence of COVID-19 and Russia-Ukraine War

- 11.5.1 Influence of COVID-19
- 11.5.2 Influence of Russia-Ukraine War

12 INDUSTRY CHAIN ANALYSIS

- 12.1 Human Immunodeficiency Virus (HIV)-1 Therapeutics Industry Chain
- 12.2 Human Immunodeficiency Virus (HIV)-1 Therapeutics Upstream Analysis
- 12.3 Human Immunodeficiency Virus (HIV)-1 Therapeutics Midstream Analysis
- 12.4 Human Immunodeficiency Virus (HIV)-1 Therapeutics Downstream Analysis

13 RESEARCH FINDINGS AND CONCLUSION

14 APPENDIX

- 14.1 Methodology
- 14.2 Research Process and Data Source
- 14.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Value by Type, (USD Million), 2018 & 2022 & 2029

Table 2. Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Value by Application, (USD Million), 2018 & 2022 & 2029

Table 3. Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Value by Region (2018-2023) & (USD Million)

Table 4. Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Value by Region (2024-2029) & (USD Million)

Table 5. AbbVie, Inc.(U.S.) Company Information, Head Office, and Major Competitors

Table 6. AbbVie, Inc.(U.S.) Major Business

Table 7. AbbVie, Inc.(U.S.) Human Immunodeficiency Virus (HIV)-1 Therapeutics Product and Solutions

Table 8. AbbVie, Inc.(U.S.) Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2023)

Table 9. AbbVie, Inc.(U.S.) Recent Developments and Future Plans

Table 10. Merck & Co., Inc. (U.S.) Company Information, Head Office, and Major Competitors

Table 11. Merck & Co., Inc. (U.S.) Major Business

Table 12. Merck & Co., Inc. (U.S.) Human Immunodeficiency Virus (HIV)-1 Therapeutics Product and Solutions

Table 13. Merck & Co., Inc. (U.S.) Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2023)

Table 14. Merck & Co., Inc. (U.S.) Recent Developments and Future Plans

Table 15. Bristol-Myers Squibb Company (U.S.) Company Information, Head Office, and Major Competitors

Table 16. Bristol-Myers Squibb Company (U.S.) Major Business

Table 17. Bristol-Myers Squibb Company (U.S.) Human Immunodeficiency Virus (HIV)-1 Therapeutics Product and Solutions

Table 18. Bristol-Myers Squibb Company (U.S.) Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2023)

Table 19. Bristol-Myers Squibb Company (U.S.) Recent Developments and Future Plans

Table 20. Boehringer Ingelheim GmbH (Germany) Company Information, Head Office, and Major Competitors

- Table 21. Boehringer Ingelheim GmbH (Germany) Major Business
- Table 22. Boehringer Ingelheim GmbH (Germany) Human Immunodeficiency Virus (HIV)-1 Therapeutics Product and Solutions
- Table 23. Boehringer Ingelheim GmbH (Germany) Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2023)
- Table 24. Boehringer Ingelheim GmbH (Germany) Recent Developments and Future Plans
- Table 25. Genentech, Inc. (U.S.) Company Information, Head Office, and Major Competitors
- Table 26. Genentech, Inc. (U.S.) Major Business
- Table 27. Genentech, Inc. (U.S.) Human Immunodeficiency Virus (HIV)-1 Therapeutics Product and Solutions
- Table 28. Genentech, Inc. (U.S.) Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2023)
- Table 29. Genentech, Inc. (U.S.) Recent Developments and Future Plans
- Table 30. Cipla, Inc. (India) Company Information, Head Office, and Major Competitors
- Table 31. Cipla, Inc. (India) Major Business
- Table 32. Cipla, Inc. (India) Human Immunodeficiency Virus (HIV)-1 Therapeutics Product and Solutions
- Table 33. Cipla, Inc. (India) Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2023)
- Table 34. Cipla, Inc. (India) Recent Developments and Future Plans
- Table 35. Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue (USD Million) by Players (2018-2023)
- Table 36. Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue Share by Players (2018-2023)
- Table 37. Breakdown of Human Immunodeficiency Virus (HIV)-1 Therapeutics by Company Type (Tier 1, Tier 2, and Tier 3)
- Table 38. Market Position of Players in Human Immunodeficiency Virus (HIV)-1 Therapeutics, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2022
- Table 39. Head Office of Key Human Immunodeficiency Virus (HIV)-1 Therapeutics Players
- Table 40. Human Immunodeficiency Virus (HIV)-1 Therapeutics Market: Company Product Type Footprint
- Table 41. Human Immunodeficiency Virus (HIV)-1 Therapeutics Market: Company Product Application Footprint
- Table 42. Human Immunodeficiency Virus (HIV)-1 Therapeutics New Market Entrants and Barriers to Market Entry

Table 43. Human Immunodeficiency Virus (HIV)-1 Therapeutics Mergers, Acquisition, Agreements, and Collaborations

Table 44. Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Value (USD Million) by Type (2018-2023)

Table 45. Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Value Share by Type (2018-2023)

Table 46. Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Value Forecast by Type (2024-2029)

Table 47. Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Value by Application (2018-2023)

Table 48. Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Value Forecast by Application (2024-2029)

Table 49. North America Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Value by Type (2018-2023) & (USD Million)

Table 50. North America Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Value by Type (2024-2029) & (USD Million)

Table 51. North America Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Value by Application (2018-2023) & (USD Million)

Table 52. North America Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Value by Application (2024-2029) & (USD Million)

Table 53. North America Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Value by Country (2018-2023) & (USD Million)

Table 54. North America Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Value by Country (2024-2029) & (USD Million)

Table 55. Europe Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Value by Type (2018-2023) & (USD Million)

Table 56. Europe Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Value by Type (2024-2029) & (USD Million)

Table 57. Europe Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Value by Application (2018-2023) & (USD Million)

Table 58. Europe Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Value by Application (2024-2029) & (USD Million)

Table 59. Europe Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Value by Country (2018-2023) & (USD Million)

Table 60. Europe Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Value by Country (2024-2029) & (USD Million)

Table 61. Asia-Pacific Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Value by Type (2018-2023) & (USD Million)

Table 62. Asia-Pacific Human Immunodeficiency Virus (HIV)-1 Therapeutics

Consumption Value by Type (2024-2029) & (USD Million)

Table 63. Asia-Pacific Human Immunodeficiency Virus (HIV)-1 Therapeutics

Consumption Value by Application (2018-2023) & (USD Million)

Table 64. Asia-Pacific Human Immunodeficiency Virus (HIV)-1 Therapeutics

Consumption Value by Application (2024-2029) & (USD Million)

Table 65. Asia-Pacific Human Immunodeficiency Virus (HIV)-1 Therapeutics

Consumption Value by Region (2018-2023) & (USD Million)

Table 66. Asia-Pacific Human Immunodeficiency Virus (HIV)-1 Therapeutics

Consumption Value by Region (2024-2029) & (USD Million)

Table 67. South America Human Immunodeficiency Virus (HIV)-1 Therapeutics

Consumption Value by Type (2018-2023) & (USD Million)

Table 68. South America Human Immunodeficiency Virus (HIV)-1 Therapeutics

Consumption Value by Type (2024-2029) & (USD Million)

Table 69. South America Human Immunodeficiency Virus (HIV)-1 Therapeutics

Consumption Value by Application (2018-2023) & (USD Million)

Table 70. South America Human Immunodeficiency Virus (HIV)-1 Therapeutics

Consumption Value by Application (2024-2029) & (USD Million)

Table 71. South America Human Immunodeficiency Virus (HIV)-1 Therapeutics

Consumption Value by Country (2018-2023) & (USD Million)

Table 72. South America Human Immunodeficiency Virus (HIV)-1 Therapeutics

Consumption Value by Country (2024-2029) & (USD Million)

Table 73. Middle East & Africa Human Immunodeficiency Virus (HIV)-1 Therapeutics

Consumption Value by Type (2018-2023) & (USD Million)

Table 74. Middle East & Africa Human Immunodeficiency Virus (HIV)-1 Therapeutics

Consumption Value by Type (2024-2029) & (USD Million)

Table 75. Middle East & Africa Human Immunodeficiency Virus (HIV)-1 Therapeutics

Consumption Value by Application (2018-2023) & (USD Million)

Table 76. Middle East & Africa Human Immunodeficiency Virus (HIV)-1 Therapeutics

Consumption Value by Application (2024-2029) & (USD Million)

Table 77. Middle East & Africa Human Immunodeficiency Virus (HIV)-1 Therapeutics

Consumption Value by Country (2018-2023) & (USD Million)

Table 78. Middle East & Africa Human Immunodeficiency Virus (HIV)-1 Therapeutics

Consumption Value by Country (2024-2029) & (USD Million)

Table 79. Human Immunodeficiency Virus (HIV)-1 Therapeutics Raw Material

Table 80. Key Suppliers of Human Immunodeficiency Virus (HIV)-1 Therapeutics Raw Materials

List Of Figures

LIST OF FIGURES

- Figure 1. Human Immunodeficiency Virus (HIV)-1 Therapeutics Picture
- Figure 2. Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
- Figure 3. Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Value Market Share by Type in 2022
- Figure 4. Nucleoside-Analog Reverse Transcriptase Inhibitors (NRTIs)
- Figure 5. Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
- Figure 6. Entry and Fusion Inhibitors
- Figure 7. Protease Inhibitors (PIs)
- Figure 8. Integrase Inhibitors
- Figure 9. Coreceptor Antagonists
- Figure 10. Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
- Figure 11. Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Value Market Share by Application in 2022
- Figure 12. Hospitals Picture
- Figure 13. Clinics Picture
- Figure 14. Labs Picture
- Figure 15. Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Value, (USD Million): 2018 & 2022 & 2029
- Figure 16. Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Value and Forecast (2018-2029) & (USD Million)
- Figure 17. Global Market Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Value (USD Million) Comparison by Region (2018 & 2022 & 2029)
- Figure 18. Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Value Market Share by Region (2018-2029)
- Figure 19. Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Value Market Share by Region in 2022
- Figure 20. North America Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Value (2018-2029) & (USD Million)
- Figure 21. Europe Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Value (2018-2029) & (USD Million)
- Figure 22. Asia-Pacific Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Value (2018-2029) & (USD Million)
- Figure 23. South America Human Immunodeficiency Virus (HIV)-1 Therapeutics

Consumption Value (2018-2029) & (USD Million)

Figure 24. Middle East and Africa Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Value (2018-2029) & (USD Million)

Figure 25. Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue Share by Players in 2022

Figure 26. Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2022

Figure 27. Global Top 3 Players Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Share in 2022

Figure 28. Global Top 6 Players Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Share in 2022

Figure 29. Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Value Share by Type (2018-2023)

Figure 30. Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Share Forecast by Type (2024-2029)

Figure 31. Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Value Share by Application (2018-2023)

Figure 32. Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Share Forecast by Application (2024-2029)

Figure 33. North America Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Value Market Share by Type (2018-2029)

Figure 34. North America Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Value Market Share by Application (2018-2029)

Figure 35. North America Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Value Market Share by Country (2018-2029)

Figure 36. United States Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Value (2018-2029) & (USD Million)

Figure 37. Canada Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Value (2018-2029) & (USD Million)

Figure 38. Mexico Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Value (2018-2029) & (USD Million)

Figure 39. Europe Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Value Market Share by Type (2018-2029)

Figure 40. Europe Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Value Market Share by Application (2018-2029)

Figure 41. Europe Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Value Market Share by Country (2018-2029)

Figure 42. Germany Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Value (2018-2029) & (USD Million)

Figure 43. France Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Value (2018-2029) & (USD Million)

Figure 44. United Kingdom Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Value (2018-2029) & (USD Million)

Figure 45. Russia Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Value (2018-2029) & (USD Million)

Figure 46. Italy Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Value (2018-2029) & (USD Million)

Figure 47. Asia-Pacific Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Value Market Share by Type (2018-2029)

Figure 48. Asia-Pacific Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Value Market Share by Application (2018-2029)

Figure 49. Asia-Pacific Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Value Market Share by Region (2018-2029)

Figure 50. China Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Value (2018-2029) & (USD Million)

Figure 51. Japan Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Value (2018-2029) & (USD Million)

Figure 52. South Korea Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Value (2018-2029) & (USD Million)

Figure 53. India Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Value (2018-2029) & (USD Million)

Figure 54. Southeast Asia Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Value (2018-2029) & (USD Million)

Figure 55. Australia Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Value (2018-2029) & (USD Million)

Figure 56. South America Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Value Market Share by Type (2018-2029)

Figure 57. South America Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Value Market Share by Application (2018-2029)

Figure 58. South America Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Value Market Share by Country (2018-2029)

Figure 59. Brazil Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Value (2018-2029) & (USD Million)

Figure 60. Argentina Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Value (2018-2029) & (USD Million)

Figure 61. Middle East and Africa Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Value Market Share by Type (2018-2029)

Figure 62. Middle East and Africa Human Immunodeficiency Virus (HIV)-1 Therapeutics

Consumption Value Market Share by Application (2018-2029)

Figure 63. Middle East and Africa Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Value Market Share by Country (2018-2029)

Figure 64. Turkey Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Value (2018-2029) & (USD Million)

Figure 65. Saudi Arabia Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Value (2018-2029) & (USD Million)

Figure 66. UAE Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Value (2018-2029) & (USD Million)

Figure 67. Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Drivers

Figure 68. Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Restraints

Figure 69. Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Trends

Figure 70. Porters Five Forces Analysis

Figure 71. Manufacturing Cost Structure Analysis of Human Immunodeficiency Virus (HIV)-1 Therapeutics in 2022

Figure 72. Manufacturing Process Analysis of Human Immunodeficiency Virus (HIV)-1 Therapeutics

Figure 73. Human Immunodeficiency Virus (HIV)-1 Therapeutics Industrial Chain

Figure 74. Methodology

Figure 75. Research Process and Data Source

I would like to order

Product name: Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market 2023 by Company, Regions, Type and Application, Forecast to 2029

Product link: <https://marketpublishers.com/r/G7E34A622529EN.html>

Price: US\$ 3,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G7E34A622529EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

